AU StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Novel Coronavirus Treatment

988.582

+5.3040.54%

Number of Gainers:6

Number of Losers:10

Number of Flat:17

PE:- -

High:991.910

Open:988.951

Low:983.649

Close:983.278

Volume:7.84M

Turnover:78.88M

Market Cap:245.34B

Float Cap:200.87B

Loading ...

Cynata Therapeutics Ltd - Termination of At

THOMSON REUTERS

Noxopharm Ltd-FDA Feedback Supports Sof-Skn Phase Ii Plans

THOMSON REUTERS

ASX Growth Stocks With High Insider Ownership October 2026

Simply Wall St.

Citi Raises CSL's PT After $1.6 Billion Alentis Deal

CSL (ASX:CSL) Backs Lixudebart As Investors Ask If The Undervalued View Still Holds

Simply Wall St.

DroneShield And 2 Australian Penny Stocks To Watch

Simply Wall St.

CSL's Alentis Licensing Deal Low-Risk, Low-Reward, RBC Capital Markets Says

MT Newswires Live

Prices Us$1,000 Mln 10-Year Notes at 6.201% Fixed Rate Coupon

THOMSON REUTERS

Settlement of Notes Expected on October 14, 2026

THOMSON REUTERS

CSL Limited-CSL Prices Us$1.5 Billion in Corporate Bonds

THOMSON REUTERS

Prices Us$500 Mln 7-Year Notes at 5.948% Fixed Rate Coupon

THOMSON REUTERS

Notes to be Issued by Cslb. and Guaranteed by CSL

THOMSON REUTERS

Proceeds to be Used to Refinance Debt and for General Corporate Purposes

THOMSON REUTERS

Citi Remains Neutral on Australia's Ansell; Says Competition Reports Steady Demand

ASX Stocks Estimated To Be Trading Below Fair Value October 2026

Simply Wall St.

Learn Why The Bull Case For CSL (ASX:CSL) Could Change Following Rare Disease Drug Partnership

Simply Wall St.

Australia's Green Institute Puts Forward AU$25 Billion Plan to Create Publicly Owned Supermarket Chain

MT Newswires Live

CSL's Licensing Deal for Lixudebart Signals Current R&D Philosophy

Jefferies Raise Price Target on Australia's CSL After Alentis Licensing Deal

Asia Morning Call-Global Markets

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/stock/BK7501/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK7501","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK7501\",,,,,undefined,":{"symbol":"BK7501","market":"AU","secType":"PLATE","nameCN":"Novel Coronavirus Treatment","latestPrice":988.58203,"timestamp":1791422832827,"preClose":983.2778,"halted":0,"volume":7839225,"delay":0,"changeRate":0.005394,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Trading","change":5.30426,"latestTime":"10-08 12:27:12 AEDT","open":988.9512,"high":991.91034,"low":983.64905,"amount":78879429,"amplitude":0.008402,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1791435600000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"openAndCloseTimeList":[[1791414000000,1791435600000]],"turnoverRate":0.000547,"increases":6,"decrements":10,"flats":16,"marketCap":245344049940.25,"floatMarketCap":200873721728.5547},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK7501\",,,,,undefined,":{"symbol":"BK7501","high":991.91034,"amplitude":0.008402,"preClose":983.2778,"low":983.64905,"latestPrice":988.58203,"volume":7839225,"delay":0,"open":988.9512,"prevYearClose":900.1661,"prevWeekClose":966.403,"prevMonthClose":999.613,"prevQuarterClose":999.613,"fiveDayClose":974.586,"twentyDayClose":948.574,"sixtyDayClose":827.945,"secType":"PLATE","market":"AU","turnoverRate":0.000547,"marketCap":245344049940.25,"floatMarketCap":200873721728.5547,"timestamp":1791422832827,"nameCN":"Novel Coronavirus Treatment"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK7501\",,,,undefined,":{"bkCode":"BK7501","up":6,"down":10,"flat":17},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK7501\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2673304353","title":"Cynata Therapeutics Ltd - Termination of At","url":"https://stock-news.laohu8.com/highlight/detail?id=2673304353","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673304353?lang=en_us&edition=fundamental","pubTime":"2026-10-08 05:27","pubTimestamp":1791408469,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261007:nFWN45T23M:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","BK7508","BK7501","CYP.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673043831","title":"Noxopharm Ltd-FDA Feedback Supports Sof-Skn Phase Ii Plans","url":"https://stock-news.laohu8.com/highlight/detail?id=2673043831","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673043831?lang=en_us&edition=fundamental","pubTime":"2026-10-08 05:15","pubTimestamp":1791407737,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261007:nTUEC8TCQ0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NOX.AU","BK7508","BK7067","BK7501"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673017001","title":"ASX Growth Stocks With High Insider Ownership October 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2673017001","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673017001?lang=en_us&edition=fundamental","pubTime":"2026-10-08 03:08","pubTimestamp":1791400080,"startTime":"0","endTime":"0","summary":"As the Australian market prepares for a potentially positive start to the week, investor sentiment remains cautious amid concerns over rising bond yields and geopolitical factors. In this environment, growth companies with high insider ownership can be appealing as they often reflect strong confidence from those closest to the business.","market":"sg","thumbnail":"https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/2052000-choice2-card/1788935149464","type":0,"news_type":0,"thumbnails":["https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/2052000-choice2-card/1788935149464"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/materials/asx-ltr/liontown-shares/news/asx-growth-stocks-with-high-insider-ownership-october-2026","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/materials/asx-ltr/liontown-shares/news/asx-growth-stocks-with-high-insider-ownership-october-2026","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK7142","BK7017","BK7104","XAO.AU","QFN.AU","IOZ.AU","IISV.AU","GEAR.AU","BK7096","PDI.AU","VAS.AU","XKO.AU","BK7093","EIGA.AU","OZF.AU","QRE.AU","WZR.AU","DVP.AU","OZR.AU","BK7110","IMLC.AU","P1E.AU","AR1.AU","BEAR.AU","STW.AU","AEM.AU","E200.AU","ZYAU.AU","BBOZ.AU","BK7095","GIVE.AU","BK7068","SKS.AU","BK7504","LTR.AU","SPL.AU","IIGF.AU","BGD.AU","FRS.AU","BK7016","BK7508","BK7023","VAP.AU","AV1.AU","SLF.AU","XJO.AU","DDR.AU","DACE.AU","BK7501"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673017859","title":"Citi Raises CSL's PT After $1.6 Billion Alentis Deal","url":"https://stock-news.laohu8.com/highlight/detail?id=2673017859","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673017859?lang=en_us&edition=fundamental","pubTime":"2026-10-08 02:43","pubTimestamp":1791398609,"startTime":"0","endTime":"0","summary":"BUZZ-Citi raises CSL's PT after $1.6 billion Alentis deal** Citi raises PT of Australia's CSLCSL.AXto A$180, sees upside in deal with Alentis** On Monday, the biotech giantsignedan agreement with Swiss drugmaker Alentis Therapeutics to co-develop and co-promote treatment for rare kidney and liver diseases, in a deal worth up to $1.6 billion** Brokerage says the deal is consistent and structurally sound aligning with company commentary** Says deal sticks within an area CSL already operates - orphan renal conditions** Sees $125 million risk adjusted sales by 2031, addresses that pipeline replenishment is a key concern for investors and sees this as a positive step** 10 of 17 analysts rate the stock \"buy\" or higher, seven \"hold\"; their median PT is A$182, LSEG-compiled data shows** YTD, stock up nearly 5.5%, as of last close","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261007:nL6N45T14G:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CSL.AU","BK7501","BK7067","BK7508","BK7511"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673019013","title":"CSL (ASX:CSL) Backs Lixudebart As Investors Ask If The Undervalued View Still Holds","url":"https://stock-news.laohu8.com/highlight/detail?id=2673019013","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673019013?lang=en_us&edition=fundamental","pubTime":"2026-10-07 22:38","pubTimestamp":1791383882,"startTime":"0","endTime":"0","summary":"CSL (ASX:CSL) has entered into an exclusive partnership with Alentis Therapeutics to co-develop lixudebart, supporting the antibody with a US$355 million upfront payment and up to US$1.2 billion in potential milestone payments.\nCSL shares have been on a strong run recently, with the 90 day share price return of 44.98% and 30 day share price return of 5.09% suggesting momentum has picked up after a weaker patch. This comes even though the 1 year total shareholder return is still down 9.23% and...","market":"nz","thumbnail":"https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/company-cover/881503-card/1789585842930","type":0,"news_type":0,"thumbnails":["https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/company-cover/881503-card/1789585842930"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-csl/csl-shares/news/csl-asxcsl-backs-lixudebart-as-investors-ask-if-the-underval","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-csl/csl-shares/news/csl-asxcsl-backs-lixudebart-as-investors-ask-if-the-underval","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4211","BK7511","BK7508","ISBC","BK7067","CSL.AU","BK7501"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673190990","title":"DroneShield And 2 Australian Penny Stocks To Watch","url":"https://stock-news.laohu8.com/highlight/detail?id=2673190990","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673190990?lang=en_us&edition=fundamental","pubTime":"2026-10-07 19:48","pubTimestamp":1791373682,"startTime":"0","endTime":"0","summary":"AI is now shaping global growth expectations, and the IMF is warning that the benefits are flowing to a narrow group of markets. That kind of concentration can leave overlooked Australian small caps looking especially interesting. Financially solid low priced companies give you exposure to early stage growth stories without only chasing the crowded AI trade. This article highlights three financially disciplined penny stocks that meet those criteria.\nThe three stocks covered below are just a...","market":"hk","thumbnail":"https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/3021000-choice2-card/1788948713663","type":0,"news_type":0,"thumbnails":["https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/3021000-choice2-card/1788948713663"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/capital-goods/asx-dro/droneshield-shares/news/droneshield-and-2-australian-penny-stocks-to-watch","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/capital-goods/asx-dro/droneshield-shares/news/droneshield-and-2-australian-penny-stocks-to-watch","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["SLF.AU","XAO.AU","BK7115","DRO.AU","BK7508","GEAR.AU","IOZ.AU","BBOZ.AU","OZR.AU","STW.AU","XKO.AU","XJO.AU","IISV.AU","GIVE.AU","OZF.AU","VAP.AU","ZYAU.AU","IIGF.AU","MSB.AU","QFN.AU","BK7083","BK7501","DACE.AU","VAS.AU","QRE.AU","BOE.AU","BEAR.AU","EIGA.AU","IMLC.AU","BK7067","E200.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673671490","title":"CSL's Alentis Licensing Deal Low-Risk, Low-Reward, RBC Capital Markets Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2673671490","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673671490?lang=en_us&edition=fundamental","pubTime":"2026-10-07 12:10","pubTimestamp":1791346251,"startTime":"0","endTime":"0","summary":"CSL's  deal with Alentis Therapeutics for Lixudebart, a therapy candidate for anti-neutrophil cytoplasmic antibodies-associated vasculitis and rapidly progressive glomerulonephritis, is low-risk but low-reward, RBC Capital Markets said in a Thursday note.It noted that the clinical and commercial aspects of Lixudebart are unknown and the timeframe to first potential commercial revenues is fairly long. The deal's PoS adjusted net present value is AU$415 million.RBC reduced CSL's earnings per share forecasts by 0.1% to 0.4% for fiscal 2027 to fiscal 2029.The brokerage assigned an outperform rating to CSL and raised the price target to AU$215 from AU$213.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7067","LU0029864427.USD","LU0310800379.SGD","LU0708994859.HKD","LU1267930573.SGD","GSIB","BK7501","BK4207","CSL.AU","LU0128525929.USD","BK7511","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673662090","title":"Prices Us$1,000 Mln 10-Year Notes at 6.201% Fixed Rate Coupon","url":"https://stock-news.laohu8.com/highlight/detail?id=2673662090","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673662090?lang=en_us&edition=fundamental","pubTime":"2026-10-07 06:24","pubTimestamp":1791325479,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261006:nTUE6JFKDF:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7508","BK7511","BK7067","BK7501","CSL.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673306620","title":"Settlement of Notes Expected on October 14, 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2673306620","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673306620?lang=en_us&edition=fundamental","pubTime":"2026-10-07 06:24","pubTimestamp":1791325479,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261006:nTUE6JFKDF:6","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","BK7501","BK7508","BK7511","CSL.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673208066","title":"CSL Limited-CSL Prices Us$1.5 Billion in Corporate Bonds","url":"https://stock-news.laohu8.com/highlight/detail?id=2673208066","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673208066?lang=en_us&edition=fundamental","pubTime":"2026-10-07 06:24","pubTimestamp":1791325479,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261006:nTUE6JFKDF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7508","BK7511","BK7067","CSL.AU","BK7501"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673066270","title":"Prices Us$500 Mln 7-Year Notes at 5.948% Fixed Rate Coupon","url":"https://stock-news.laohu8.com/highlight/detail?id=2673066270","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673066270?lang=en_us&edition=fundamental","pubTime":"2026-10-07 06:24","pubTimestamp":1791325479,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261006:nTUE6JFKDF:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7501","BK7067","BK7511","CSL.AU","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673066206","title":"Notes to be Issued by Cslb. and Guaranteed by CSL","url":"https://stock-news.laohu8.com/highlight/detail?id=2673066206","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673066206?lang=en_us&edition=fundamental","pubTime":"2026-10-07 06:24","pubTimestamp":1791325479,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261006:nTUE6JFKDF:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CSL.AU","BK7067","BK7501","BK7508","BK7511"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673066205","title":"Proceeds to be Used to Refinance Debt and for General Corporate Purposes","url":"https://stock-news.laohu8.com/highlight/detail?id=2673066205","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673066205?lang=en_us&edition=fundamental","pubTime":"2026-10-07 06:24","pubTimestamp":1791325479,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261006:nTUE6JFKDF:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7501","CSL.AU","BK7067","BK7508","BK7511"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673680470","title":"Citi Remains Neutral on Australia's Ansell; Says Competition Reports Steady Demand","url":"https://stock-news.laohu8.com/highlight/detail?id=2673680470","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673680470?lang=en_us&edition=fundamental","pubTime":"2026-10-07 03:42","pubTimestamp":1791315765,"startTime":"0","endTime":"0","summary":"BUZZ-Citi remains neutral on Australia's Ansell; says competition reports steady demand** Analysts at Citi maintain a neutral rating for Australian medical glove maker AnsellANN.AX, with its price tar","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261006:nL4N45S1D6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7126","ANN.AU","BK7501"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673634110","title":"ASX Stocks Estimated To Be Trading Below Fair Value October 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2673634110","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673634110?lang=en_us&edition=fundamental","pubTime":"2026-10-07 03:04","pubTimestamp":1791313485,"startTime":"0","endTime":"0","summary":"As the Australian share market opens with mixed signals, investors are keeping a close eye on bond yields and geopolitical factors that could influence market sentiment. In this environment, identifying stocks trading below their fair value can be crucial for investors looking to capitalize on potential opportunities amidst ongoing uncertainties.","market":"hk","thumbnail":"https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/2053000-choice1-card/1788945647432","type":0,"news_type":0,"thumbnails":["https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/2053000-choice1-card/1788945647432"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/materials/asx-ggp/greatland-resources-shares/news/asx-stocks-estimated-to-be-trading-below-fair-value-october","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/materials/asx-ggp/greatland-resources-shares/news/asx-stocks-estimated-to-be-trading-below-fair-value-october","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK7507","SGLLV.AU","BK7142","LBL.AU","ANN.AU","QAL.AU","WDS.AU","BK7062","BK7126","BK7506","BK7088","BK7089","BK7130","BK4585","WGX.AU","BK7143","NOL.AU","BK7501","BK7104","ORG.AU","BK7121","BK7006","BK7141","BK4588","SPHQ","MTO.AU","GGP.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673055216","title":"Learn Why The Bull Case For CSL (ASX:CSL) Could Change Following Rare Disease Drug Partnership","url":"https://stock-news.laohu8.com/highlight/detail?id=2673055216","media":"Simply Wall St.","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673055216?lang=en_us&edition=fundamental","pubTime":"2026-10-06 17:19","pubTimestamp":1791278359,"startTime":"0","endTime":"0","summary":"CSL and Alentis Therapeutics recently agreed an exclusive global collaboration to co-develop and co-promote lixudebart for rare kidney and liver diseases, with CSL funding Phase 2 and Phase 3 programs and Alentis eligible for a US$355 million upfront payment plus up to US$1.2b in milestones and shared profits.\nThe structure of the lixudebart deal, with CSL taking on full development funding and a 55% share of global profits, signals a clear commitment to expand its nephrology and rare...","market":"hk","thumbnail":"https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/company-cover/881503-card/1789585842930","type":0,"news_type":0,"thumbnails":["https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/company-cover/881503-card/1789585842930"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-csl/csl-shares/news/learn-why-the-bull-case-for-csl-asxcsl-could-change-followin","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-csl/csl-shares/news/learn-why-the-bull-case-for-csl-asxcsl-could-change-followin","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK7501","CSL.AU","BK7511","BK7067","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673038654","title":"Australia's Green Institute Puts Forward AU$25 Billion Plan to Create Publicly Owned Supermarket Chain","url":"https://stock-news.laohu8.com/highlight/detail?id=2673038654","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673038654?lang=en_us&edition=fundamental","pubTime":"2026-10-06 09:23","pubTimestamp":1791249832,"startTime":"0","endTime":"0","summary":"The Green Institute, the policy think tank and research organization for the Australian Greens political party, unveiled a plan to create a national network of publicly owned supermarkets called Fair ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["QRE.AU","BBOZ.AU","BK7040","EIGA.AU","BK7501","IIGF.AU","IOZ.AU","BEAR.AU","ZYAU.AU","IMLC.AU","WOW.AU","BK7082","OZR.AU","SLF.AU","XJO.AU","XKO.AU","DACE.AU","BK7511","IISV.AU","GEAR.AU","E200.AU","OZF.AU","XAO.AU","GIVE.AU","COL.AU","QFN.AU","VAS.AU","VAP.AU","STW.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673824820","title":"CSL's Licensing Deal for Lixudebart Signals Current R&D Philosophy","url":"https://stock-news.laohu8.com/highlight/detail?id=2673824820","media":"Dow Jones","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673824820?lang=en_us&edition=fundamental","pubTime":"2026-10-06 05:50","pubTimestamp":1791237000,"startTime":"0","endTime":"0","summary":"2149 GMT - CSL's deal with Alentis Therapeutics to jointly develop and promote a rare kidney and liver disease treatment is emblematic of its current research and development philosophy, suggests Jeff","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7508","BK7511","BK7067","BK7501","CSL.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673708453","title":"Jefferies Raise Price Target on Australia's CSL After Alentis Licensing Deal","url":"https://stock-news.laohu8.com/highlight/detail?id=2673708453","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673708453?lang=en_us&edition=fundamental","pubTime":"2026-10-06 04:33","pubTimestamp":1791232419,"startTime":"0","endTime":"0","summary":"BUZZ-Jefferies raise price target on Australia's CSL after Alentis licensing deal** Jefferies raise CSL'sCSL.AXprice target to A$161.50 from A$146.50 after companylicensedlixudebart, a Phase 2 anti-fi","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261005:nL4N45R1C9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7511","BK7067","CSL.AU","BK7501","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673089924","title":"Asia Morning Call-Global Markets","url":"https://stock-news.laohu8.com/highlight/detail?id=2673089924","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673089924?lang=en_us&edition=fundamental","pubTime":"2026-10-06 02:30","pubTimestamp":1791225047,"startTime":"0","endTime":"0","summary":"Asia Morning Call-Global MarketsOct 6 (Reuters)-Stock MarketsNet ChngStock MarketsNet ChngS&P/ASX 200**8,686.4073.50NZX 50**13,699.0218.53DJIA51,310.49139.86NIKKEI**69,946.41,637.40Nasdaq27,437.26-25.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261005:nL4N45R15R:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7511","BK7067","CSL.AU","BK7501","BK7508"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":5,"pageCount":1,"totalSize":81,"code":"91000000","status":"200"}]}}